ReviewHeart failure reviews2009
Vasodilators in the treatment of acute heart failure: what we know, what we don't.
Review in Heart failure reviews, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 58 citations in OpenAlex.
- A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure.European heart journal · 2014Trial
- Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study.European journal of heart failure · 2010Trial
- Biologics for cardiovascular diseases: from bench to bedside.Signal transduction and targeted therapy · 2026Review
- COVID-19 and Progesterone: Part 2. Unraveling High Severity, Immunity Patterns, Immunity grading, Progesterone and its potential clinical use.Endocrine and metabolic science · 2021Article
- Management of Acute Heart Failure during an Early Phase.International journal of heart failure · 2020Review
- Medication adherence and survival among hospitalized heart failure patients in a tertiary hospital in Tanzania: a prospective cohort study.BMC research notes · 2020Article
- Role of Nitric Oxide Carried by Hemoglobin in Cardiovascular Physiology: Developments on a Three-Gas Respiratory Cycle.Circulation research · 2020Review
- Therapeutic effects of intravenous urapidil in elderly patients with hypertension and acute decompensated heart failure: A pilot clinical trial.Experimental and therapeutic medicine · 2016Article
- Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection.European heart journal. Cardiovascular pharmacotherapy · 2016Review
- Impact of Nitrate Use on Survival in Acute Heart Failure: A Propensity-Matched Analysis.Journal of the American Heart Association · 2016Article
- Factors associated with 30-day readmission of patients with heart failure from a Japanese administrative database.BMC cardiovascular disorders · 2015Observational
- Challenges in acute heart failure clinical management: optimizing care despite incomplete evidence and imperfect drugs.Critical pathways in cardiology · 2015Review
- Serelaxin: a novel therapy for acute heart failure with a range of hemodynamic and non-hemodynamic actions.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2014Review
- The potential value of integrated natriuretic peptide and echo-guided heart failure management.Cardiovascular ultrasound · 2014Review
- Serelaxin, a 'breakthrough' investigational intravenous agent for acute heart failure.P & T : a peer-reviewed journal for formulary management · 2013Article
- Can we prevent or treat renal dysfunction in acute heart failure?Heart failure reviews · 2012Review
- Novel therapeutic targets for the treatment of heart failure.Nature reviews. Drug discovery · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although we have recently witnessed substantial progress in management and outcome of patients with chronic heart failure, acute heart failure (AHF) management and outcome have not changed over almost a generation. Vasodilators are one of the cornerstones of AHF management; however, to a large extent, none of those currently used has been examined by large, placebo-controlled, non-hemodynamic monitored, prospective randomized studies powered to assess the effects on outcomes, in addition to symptoms. In this article, we will discuss the role of vasodilators in AHF trying to point out which are the potentially best indications to their administration and which are the pitfalls which may be associated with their use. Unfortunately, most of this discussion is only partially evidence based due to lack of appropriate clinical trials. In general, we believe that vasodilators should be administered early to AHF patients with normal or high blood pressure (BP) at presentation. They should not be administered to patients with low BP since they may cause hypotension and hypoperfusion of vital organs, leading to renal and/or myocardial damage which may further worsen patients' outcome. It is not clear whether vasodilators have a role in either patients with borderline BP at presentation (i.e., low-normal) or beyond the first 1-2 days from presentation. Given the limitations of the currently available clinical trial data, we cannot recommend any specific agent as first line therapy, although nitrates in different formulations are still the most widely used in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.